Three months and a lifespan, in female C57BL/6 mice
Semaglutide was given daily by subcutaneous injection to 20-month-old female C57BL/6 mice, an age at which the strain's decline is already under way. In the lifespan arm the treatment ran to the end of life, and the median lifespan came out at 742 days in the control group against 834 days in the treated group. The physiology was carried by a separate cohort treated for 3 months: more movement and exploration in a novel environment, longer time in the target quadrant of the Barnes maze test, a longer latency to fall from the rotarod, and faster glucose clearance in the glucose-tolerance test. The same regimen reduced food intake by 24 per cent. The paper is peer reviewed in Nature, and these animals are the whole of its lifespan evidence.[1]
The comparison that gives the result its shape ran for 5 months: vehicle, semaglutide, or a matched 24 per cent calorie restriction in the same 20-month-old female C57BL/6 mice, assessed at the baseline and after 2 or 4 months of treatment. Weight and fat loss came out comparable while the feeding patterns diverged: the calorie-restricted animals took their daily allotment quickly and then held a long fast, and the semaglutide animals ate more gradually through the day with appetite suppressed. Against that comparator semaglutide held function at the baseline across most measures and rose above the baseline in exploratory drive, spatial memory and glucose control. The authors read this as a calorie-restriction mimetic whose effects extend past reduced intake alone.[1]
What makes up the denominator: one C57BL/6 strain, one sex
Female mice were selected to minimize confounding effects of male aggression and injury, a standard choice in long-term ageing work that leaves the male half of the question unmeasured. One strain, C57BL/6, carries the lifespan curve. Within the end points monitored, no adverse effects attributable to semaglutide were observed; that sentence covers what was watched in these animals over these months, and it stops there. The authors are explicit on the last point: whether GLP-1R activation modulates ageing trajectories and lifespan in humans will require long-term clinical studies designed to evaluate ageing-related outcomes in older populations.[1]
The human end of the same question this week is a cross-section. Routine clinical data from 104,208 adults aged 18 to 98 at three centres in China went into sex-specific aging clocks built from 172 commonly measured indicators; men showed a metabolic transition at 35–45, women a later one at 55–65 around menopause, and the difference between the sexes narrowed in later life. The cross-sectional study appears in Nature Aging, and its design compares people of different ages at one point in time rather than following the same people forward. Set beside a mouse arm that followed animals to death, it shows where the ageing literature currently keeps its time axis: in the animal.[1], [2]
In two Nature Aging results the causal step sits in the animal
The second Nature Aging paper follows the same shape. Bifidobacterium pseudocatenulatum falls sharply with age in Chinese cohorts in both men and women, and people carrying more of it score younger on the MicroAge clock; the link there is an association. The causal step comes from the mouse experiment: feeding aged mice the bacterium's metabolite, 5-aminovaleric acid betaine, improved memory, motor coordination and mood-related behaviour and reduced low-grade inflammation in liver, lung, muscle, kidney, heart and spleen. The aging-clock paper carries its own animal and cell work: glucose, lipids, uric acid and the tumour markers CEA and HE4 induced aging-related changes in vascular endothelial cells, metformin eased the high-glucose effect, and moving mice from a high-fat diet to a normal diet improved several liver aging features. The authors of the metabolite work say clinical use awaits human trials.[3], [2]
The route that takes any of this to a clinic is the same in all three: older people, in randomly assigned arms, followed long enough for an outcome that matters to them, with that outcome named before the study starts. A median mouse lifespan of 834 days against 742, a metabolite that lifts behaviour in aged mice, and a metabolic turning point read off 104,208 adults at one moment stand three different distances from that standard. GLP-1 medicines are already widely used clinically for weight and glucose, so the population the question needs is partly assembled; the study that asks it is not yet in place. The first signal to watch is a registered clinical study in older adults naming an ageing-related outcome.[1], [2], [3]